Drug Trial Radar · NCT07027111
Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP
Last checked: Nov 20, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
14
Actual
Start
Apr 25, 2025
Primary completion
Oct 1, 2026
Study completion Oct 1, 2026
Sponsor
- Lead sponsor
- Nuvig Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the safety of NVG-2089 and to evaluate how well patients respond to this investigational treatment. NVG-2089 is a new drug that is being developed for treating patients with CIDP. NVG-2089 is designed to mimic the effects of a protein called IVIg. NVG-2089 is designed to potentially help the immune system by attaching (binding) to certain receptors in the body and activating them, which helps reduce inflammation and supports how the immune system works.
Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy
Interventions
NVG-2089Drug
Study drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate incidence, nature and severity of TEAE'sTime frame: Week 14
- Evaluate incidence, nature and severity of SAE'sTime frame: Week 14
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nuvig Site
Denton, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.